Cumulative live birth rates in low-prognosis women by Leijdekkers, J.A. (Jori A.) et al.
†OPTIMIST study group authors are listed in the Appendix
© The Author(s) 2019. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which per-
mits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
Human Reproduction, Vol.34, No.6, pp. 1030–1041, 2019
Advance Access Publication on May 23, 2019 doi:10.1093/humrep/dez051
ORIGINAL ARTICLE Infertility
Cumulative live birth rates in
low-prognosis women
Jori A. Leijdekkers1,*,Marinus J.C. Eijkemans2,
Theodora C. van Tilborg1, Simone C.Oudshoorn1,
Ron J.T. van Golde3, Annemieke Hoek4, Cornelis B. Lambalk5,
Jan Peter de Bruin6, Kathrin Fleischer7,Monique H.Mochtar8,
Walter K.H. Kuchenbecker9, Joop S.E. Laven10, Ben Willem J.Mol11,
Helen L. Torrance1, Frank J.M. Broekmans1, and on behalf of the
OPTIMIST study group†
1Department of Reproductive Medicine and Gynaecology, University Medical Centre Utrecht, Utrecht University, Heidelberglaan 100, 3584
CX Utrecht, The Netherlands 2Julius Centre for Health Sciences and Primary Care, University Medical Centre Utrecht, Utrecht University,
Heidelberglaan 100, 3584 CX Utrecht, The Netherlands 3Department of Reproductive Medicine, Maastricht University Medical Centre, P.
Debyelaan 25, 6229 HX Maastricht, The Netherlands 4Centre for Reproductive Medicine, University Medical Centre Groningen, University
of Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands 5Centre for Reproductive Medicine, Amsterdam University Medical
Centre, Free University of Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands 6Department of Obstetrics and
Gynaecology, Jeroen Bosch Hospital, Henri Dunantstraat 1, 5223 GZ ’s-Hertogenbosch, The Netherlands 7Department of Obstetrics and
Gynaecology, Radboud University Medical Centre, Geert Grooteplein Zuid 10, 6525 GA Nijmegen, T he Netherlands 8Centre for
Reproductive Medicine, Amsterdam University Medical Centre, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The
Netherlands 9Department of Obstetrics and Gynaecology, Isala Clinics, Dokter Spanjaardweg 27-29, 8025 BT Zwolle, The Netherlands
10Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynaecology, Erasmus University Medical Centre,
Doctor Molewaterplein 40, 3015 GD Rotterdam, The Netherlands 11Department of Obstetrics and Gynaecology, Monash University,
Scenic Blvd & Wellington Road, Clayton, VIC 3800, Australia
*Correspondence address. Department of Reproductive Medicine and Gynaecology, University Medical Centre Utrecht, Utrecht University,
Heidelberglaan 100, 3584 CX Utrecht, The Netherlands. E-mail: j.a.leijdekkers@umcutrecht.nl
Submitted on October 22, 2018; resubmitted on March 10, 2019; editorial decision on March 27, 2019
STUDY QUESTION: Do cumulative live birth rates (CLBRs) over multiple IVF/ICSI cycles conﬁrm the low prognosis in women stratiﬁed
according to the POSEIDON criteria?
SUMMARY ANSWER: The CLBR of low-prognosis women is ∼56% over 18 months of IVF/ICSI treatment and varies between the
POSEIDON groups, which is primarily attributable to the impact of female age.
WHAT IS KNOWN ALREADY: The POSEIDON group recently proposed a new stratiﬁcation for low-prognosis women in IVF/ICSI
treatment, with the aim to deﬁne more homogenous populations for clinical trials and stimulate a patient-tailored therapeutic approach. These
new criteria combine qualitative and quantitative parameters to create four groups of low-prognosis women with supposedly similar biologic
characteristics.
STUDY DESIGN, SIZE, DURATION: This study analyzed the data of a Dutch multicenter observational cohort study including 551 low-
prognosis women, aged <44 years, who initiated IVF/ICSI treatment between 2011 and 2014 and were treated with a ﬁxed FSH dose of
150 IU/day in the ﬁrst treatment cycle.
PARTICIPANTS/MATERIALS, SETTING, METHODS: Low-prognosis women were categorized into one of the POSEIDON groups
based on their age (younger or older than 35 years), anti-Müllerian hormone (AMH) level (above or below 0.96 ng/ml), and the ovarian
response (poor or suboptimal) in their ﬁrst cycle of standard stimulation. The primary outcome was the CLBR over multiple complete IVF/ICSI
cycles, including all subsequent fresh and frozen-thawed embryo transfers, within 18 months of treatment. Cumulative incidence curves were
obtained using an optimistic and a conservative analytic approach.
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MAIN RESULTS AND THE ROLE OF CHANCE: The CLBR of the low-prognosis women was on average ∼56% over 18 months of
IVF/ICSI treatment. Younger unexpected poor (n=38) and suboptimal (n=179) responders had a CLBR of ∼65% and∼68%, respectively, and
younger expected poor responders (n =65) had a CLBR of ∼59%. The CLBR of older unexpected poor (n =41) and suboptimal responders
(n =102) was ∼42% and ∼54%, respectively, and of older expected poor responders (n =126) ∼39%. For comparison, the CLBR of younger
(n =164) and older (n =78) normal responders with an adequate ovarian reserve was ∼72% and ∼58% over 18 months of treatment,
respectively. No large differences were observed in the number of fresh treatment cycles between the POSEIDON groups, with an average
of two fresh cycles per woman within 18 months of follow-up.
LIMITATIONS, REASONS FOR CAUTION: Small numbers in some (sub)groups reduced the precision of the estimates. However, our
ﬁndings provide the ﬁrst relevant indication of the CLBR of low-prognosis women in the POSEIDON groups. Small FSH dose adjustments
between cycles were allowed, inducing therapeutic disparity. Yet, this is in accordancewith current daily practice and increases the generalizability
of our ﬁndings.
WIDER IMPLICATIONS OF THE FINDINGS: The CLBRs vary between the POSEIDON groups. This heterogeneity is primarily
determined by a woman’s age, reﬂecting the importance of oocyte quality. In younger women, current IVF/ICSI treatment reaches relatively
high CLBR over multiple complete cycles, despite reduced quantitative parameters. In older women, the CLBR remains relatively low over
multiple complete cycles, due to the co-occurring decline in quantitative and qualitative parameters. As no effective interventions exist to
counteract this decline, clinical management currently relies on proper counselling.
STUDY FUNDING/COMPETING INTEREST(S): No external funds were obtained for this study. J.A.L. is supported by a Research
Fellowship grant and received an unrestricted personal grant from Merck BV. S.C.O., T.C.v.T., and H.L.T. received an unrestricted personal
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Merck Serono, Ferring, and GoodLife. She also received fees for lectures and consultancy from Ferring and GoodLife. A.H. declares that
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Introduction
In IVF/ICSI treatment, one of the main challenges is the management
of women with an impaired ovarian reserve or a reduced response
to exogenous gonadotropins. These ‘poor responders’ generally
have lower live birth rates and higher treatment discontinuation
rates (Olivius et al., 2004; Busnelli et al., 2015; Polyzos et al., 2018).
The deﬁnition of the poor responder has been standardized in
the Bologna criteria (Ferraretti et al., 2011). However, questions
have been raised about the capacity of these criteria to select
homogenous populations for clinical trials (Ferraretti and Gianaroli,
2014; Papathanasiou, 2014). Considerable variation is seen in
baseline characteristics and prognosis due to the several ways the
Bologna criteria can be fulﬁlled. This heterogeneity is associated with
differences in the underlying etiology, and may cause variation in the
effectiveness of interventions (Papathanasiou, 2014). Therefore,
analysis of the poor responder population as a whole as deﬁned
by the Bologna criteria might dilute potential treatment effects
and could prevent the progress in clinical management for speciﬁc
subpopulations.
In 2016, the POSEIDON group proposed a more subtle stratiﬁca-
tion of ‘low-prognosis women’ (Poseidon group et al., 2016). In this
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concept, women are categorized into four groups based on female
age, ovarian reserve tests (anti-Müllerian hormone (AMH) or antral
follicle count (AFC)), and the ovarian response in case of a previous
stimulation (Table I). The proposed classiﬁcation identiﬁes womenwith
an adequate ovarian reserve and a poor or suboptimal response to
standard stimulation (unexpected poor or suboptimal responders) and
women with an impaired ovarian reserve (expected poor respon-
ders). It attempts to differentiate between relevant subpopulations
of women, in whom speciﬁc interventions might be beneﬁcial. The
POSEIDON criteria could thereby improve the homogeneity and com-
parability of clinical trials, decrease the dilution of potential treatment
effects, and guide a more patient-tailored approach for low-prognosis
women (Humaidan et al., 2016; Poseidon group et al., 2016).
Although a recent trial already used the POSEIDON criteria to
select their study population (Xu et al., 2018), the actual prognosis
of the low-prognosis women has not yet been properly investigated.
Such information could help to validate the new POSEIDON con-
cept and provides an initial insight in the necessity of new interven-
tions for each group. Therefore, the current study aims to evaluate
the cumulative live birth rate (CLBR) of the POSEIDON groups
over multiple complete IVF/ICSI cycles, including all subsequent fresh
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Table I The proposed POSEIDON groups of women with a low prognosis in IVF/ICSI treatment based on quantitative
and qualitative parameters. AFC, antral follicle count; AMH, anti-Müllerian hormone; adapted from Poseidon group
et al. (2016).
Low-prognosis women in IVF/ICSI treatment
Younger Older
.....................................................................................................................................................................................
Unexpected POSEIDON group 1 POSEIDON group 2
• Female age: <35 years • Female age: ≥35 years
• Ovarian biomarkers: AFC≥ 5 and/or AMH≥ 1.2 ng/ml • Ovarian biomarkers: AFC≥ 5 and/or AMH≥ 1.2 ng/ml
• Ovarian response: • Ovarian response:
subgroup 1a, poor (<4 oocytes); subgroup 2a, poor (<4 oocytes);
subgroup 1b, suboptimal (4–9 oocytes) subgroup 2b, suboptimal (4–9 oocytes)
Expected POSEIDON group 3 POSEIDON group 4
• Female age: <35 years • Female age: ≥35 years
• Ovarian biomarkers: AFC< 5 and/or AMH< 1.2 ng/ml • Ovarian biomarkers: AFC< 5 and/or AMH< 1.2 ng/ml
POSEIDON group 1 and 2 are each divided in two subgroups (a and b), based on the ﬁrst cycle ovarian response to standard FSH stimulation.
and frozen-thawed embryo transfers (FET), within 18 months of
treatment.
Materials and Methods
Study design and population
Data of a recent Dutch multicenter prospective cohort study
(OPTIMIST study), which included 1515 women between 2011 and
2014, were used for the analyses (NTR2657). Participants were aged
<44 years, had regular menstrual cycles, and no signiﬁcant abnor-
malities on transvaginal ultrasound. Women with polycystic ovarian
syndrome, metabolic or endocrine abnormalities, or undergoing
oocyte donation were excluded. All participants had their ﬁrst IVF/ICSI
cycle, or the ﬁrst after a previous live birth. A more detailed study
description was reported previously (van Tilborg et al., 2017a).
For the current study, we included low-prognosis women, who
used a ﬁxed FSH dose of 150 IU/day in the ﬁrst cycle. Small dose
adjustments between cycles were permitted, based on the response
in the preceding cycle (van Tilborg et al., 2012). We categorized all
women in the POSEIDON groups by using age, AMH, and the ovarian
response in the ﬁrst cycle (Poseidon group et al., 2016).We usedAMH,
as recent studies indicate that it may be a more accurate and robust
biomarker than the AFC (Fleming et al., 2015; Iliodromiti and Nelson,
2015; Nelson et al., 2015a). Women with an adequate ovarian reserve
and a normal response to stimulation (deﬁned as 10–15 retrieved
oocytes), whom are generally considered to have an optimal prognosis
(Sunkara et al., 2011; Polyzos et al., 2018), were added to compare the
CLBR to low-prognosis women.
AMH measurement
In the OPTIMIST study, blood sampling was performed prior to the
start of stimulation in the early follicular phase, and AMH levels were
determined in one batch by using the fully automatic Elecsys assay
(Roche Diagnostics, Germany). As automated assays produce substan-
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tially lower values than the pre-existing enzyme linked immunosorbent
assays (ELISA) (Gassner and Jung, 2014; Nelson et al., 2015b), and as
the POSEIDON cut-off value of 1.2 ng/ml is based on studies evalu-
ating the pre-existing assays (Humaidan et al., 2016), we adjusted the
cut-off value to 0.96 ng/ml using the formula Elecsys = 0.087+ (0.729
∗ Gen II ELISA) (Nelson et al., 2015b). This formula corresponds with
our internal laboratory comparison of the Gen II ELISAwith the Elecsys
assay, which was carried out when the latter was implemented in our
hospital at the beginning of 2018 (unpublished data).
Statistical analysis
The proportion of missing AMH values was 11.6%. As the missing
values were related to logistic issues, they were considered to be
missing completely at random and multiple imputation was performed
(Sterne et al., 2009; Janssen et al., 2010) In this process, hundred
imputed datasets were created using a multivariate imputation by
chained equations algorithm (van Buuren and Groothuis-Oudshoorn,
2011). In each of the imputed datasets, women were classiﬁed in one
of the POSEIDON groups, and results were pooled by assigning the
women into the group that occurred in more than half (i.e. at least 51
out of 100) of the imputed datasets.
The primary outcome was the CLBR of the POSEIDON groups
over multiple complete IVF/ICSI cycles, including all subsequent
fresh and FET cycles, within 18 months of treatment. Additionally,
we calculated the live birth rate (LBR) per consecutive cycle,
per started stimulation, per oocyte retrieval, and per embryo
transfer. All live births, irrespective of the mode of conception,
were taken into account. Time to ongoing pregnancy leading to
live birth was depicted by cumulative incidence curves, for which
we used two approaches. First, a life table analysis (optimistic)
assumed that the chances for couples who discontinue treatment
would have been equal to couples who continue. Second, a
competing risk approach (conservative) assumed that couples
who discontinue treatment would have had zero chances of
conceiving. The realistic curve is considered to lie between these
two curves (Stolwijk et al., 1996). To measure whether signiﬁ-
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Figure 1 Flowchart of the study population of low-prognosis women according to the POSEIDON criteria (Poseidon group et al.,
2016). ∗These twelve women were not assigned to the same group in more than half of the hundred imputed datasets. aHyper response,>15 retrieved
oocytes or cycle cancellation for too many follicles according to the POSEIDON criteria. bNormal response, 10–15 retrieved oocytes according to the
POSEIDON criteria. cPoor response, <4 retrieved oocytes or cycle cancellation for insufficient follicular growth according to the POSEIDON criteria.
dSuboptimal response, 4–9 retrieved oocytes according to the POSEIDON criteria. AMH, anti-Müllerian hormone.
cant differences exist between the POSEIDON groups, a (pair-
wise) log-rank test was performed. P-values were adjusted using
the Hommel correction for multiple testing (Hommel, 1988). A
P-value of <0.05 was considered to indicate a statistically signiﬁcant
difference.
Statistical analyses were performed using R for Windows (version
3.3.2; R Foundation for Statistical Computing, Vienna, Austria).
Ethical approval
Ethical approval was obtained by the Institutional Review Board of
the University Medical Centre (MEC 10-273), and by the board of
directors of the participating centres. All participants provided written
informed consent.
Results
In the OPTIMIST study, 985 women received a ﬁxed FSH dose of
150 IU/day in the ﬁrst cycle. A total of 551 (55.9%) women met the
POSEIDON criteria and were categorized in the pre-deﬁned groups
(Fig. 1). Thesewomen underwent 1128 fresh and 329 FET cycles during
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the 18 months of follow-up. Additionally, 164 younger and 78 older
normal responders were included for supplemental comparison.
Baseline and treatment characteristics
Table II shows the baseline and treatment characteristics. By deﬁnition,
POSEIDON groups 2 and 4 had a higher age than group 1 and 3, and
AMH levels were higher in POSEIDON groups 1 and 2 compared to
groups 3 and 4. Younger unexpected poor responders (subgroup 1a)
had a higher body weight than the other (sub)groups. Primary infertility
occurred more often in the younger POSEIDON groups (1 and 3),
and they were most often treated for male factor infertility, whereas
unexplained infertility occurred more frequently in the older groups
(2 and 4).
The majority of low-prognosis women (75%) were treated with a
GnRH agonist, and ICSI was most often performed in the younger
POSEIDON groups (1 and 3). Unexpected suboptimal responders
(subgroups 1b and 2b) had the lowest number of fresh and highest
number of FET cycles. Unexpected poor responders (subgroup 1a and
2a) had the highest cancellation rates, and the FSH dose was increased
(∼60 IU/day) between cycle 1 and 2 in the majority of the expected
or unexpected poor responders (subgroups 1a and 2a, groups 3
and 4). It should be noted that these features are likely to be related to
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the characteristics that determined the assignment to the POSEIDON
(sub)groups.
Cumulative live birth rates
In low-prognosis women, the average CLBR over 18 months of
IVF/ICSI treatment was between 54% (conservative) and 57%
(optimistic) (Table III). Figure 2 shows the cumulative incidence curves
for each of the POSEIDON groups, and Table IV presents the
results of the pairwise log-rank tests. The younger groups (1 and
3) had the highest CLBR over 18 months of treatment (Table III),
and these groups also had the highest LBR per stimulation, oocyte
retrieval, and embryo transfer. Within group 1, small differences were
observed between the unexpected poor (subgroup 1a) and suboptimal
responders (subgroup 1b). The older groups (2 and 4) had lower
CLBR over 18 months of treatment. Within group 2, unexpected
suboptimal responders (subgroup 2b) seemed to have higher CLBR
than unexpected poor responders (subgroup 2a), although this
difference was not statistically signiﬁcant (Table IV). Older women with
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an impaired ovarian reserve (group 4) had the lowest CLBR, but still
reached a rate between 37% (conservative) and 41% (optimistic) over
18 months of treatment (Table III). During the 18 months of follow-
up, there were no large differences in the number of fresh treatment
cycles between the POSEIDON groups with an average of 2 cycles
per woman (Table II), yet women with the lowest prognosis (subgroup
2a and group 4) had a slightly higher number of fresh cycles (2.5 and
2.3 fresh cycles, respectively (Table II)).
Supplementary Figure S1 shows the cumulative incidence curves of
the younger (<35 years) and older (≥35 years) normal responders.
The CLBR for the younger normal responders was ∼72%, and for
the older normal responders ∼58% over 18 months of treatment
(Supplementary Table S1).
Discussion
This multicenter observational cohort study evaluated the CLBR
of low-prognosis women according to the POSEIDON criteria and
Table II Baseline and treatment characteristics of low-prognosis women stratiﬁed according to the POSEIDON criteria
( Poseidon group et al., 2016).
POSEIDON 1 POSEIDON 2 POSEIDON 3 POSEIDON 4
All
low-prognosis
women
(n=551)
Subgroup 1a;
younger
unexpected
poor
responder
(n=38)
Subgroup 1b;
younger
unexpected
suboptimal
responder
(n=179)
Subgroup 2a;
older
unexpected
poor
responder
(n=41)
Subgroup 2b;
older
unexpected
suboptimal
responder
(n=102)
Younger
expected
poor
responder
(n=65)
Older
expected
poor
responder
(n=126)
.....................................................................................................................................................................................
Baseline characteristics
Female age (years) 34.4 (4.5) 30.5 (2.7) 30.6 (2.8) 37.9 (2.0) 37.7 (2.1) 31.3 (2.7) 38.7 (2.2)
Infertility duration (years) 2.7 (1.8) 2.8 (2.0) 2.7 (1.5) 2.8 (2.0) 2.7 (2.1) 2.9 (1.4) 2.7 (2.1)
Body weight (kg) 71 (14) 81 (15) 70 (13) 74 (15) 67 (13) 72 (12) 71 (14)
Smoking (yes/no) 102 (18.5) 11 (29) 37 (20.7) 7 (17) 12 (11.8) 11 (17) 24 (19.0)
Primary infertility 319 (57.9) 30 (79) 123 (68.7) 18 (44) 45 (44.1) 47 (72) 56 (44.4)
Cause of infertility
Unexplained 209 (37.9) 8 (21) 52 (29.1) 14 (34) 47 (46.1) 12 (19) 76 (60.3)
Tubal factor 49 (8.9) 2 (5) 12 (6.7) 7 (17) 13 (12.7) 9 (14) 6 (4.8)
Endometriosis 18 (3.3) 0 (0) 9 (5.0) 1 (2) 3 (2.9) 2 (3) 3 (2.4)
Male factor 297 (53.9) 30 (79) 116 (64.8) 21 (51) 44 (43.1) 42 (65) 44 (34.9)
AFC, median (IQR) 12 (6) 13 (5) 13 (4) 12 (3) 12 (5) 9 (5) 8 (5)
AMH, median (IQR) 1.32 (1.36) 1.98 (1.34) 2.00 (1.10) 1.31 (0.45) 1.95 (0.78) 0.69 (0.21) 0.55 (0.39)
Treatment characteristics
ICSI 237 (43.0) 27 (71) 101 (56.4) 12 (29) 31 (30.4) 31 (48) 35 (27.8)
GnRH agonist 414 (75.1) 28 (74) 140 (78.2) 22 (54) 76 (74.5) 53 (82) 95 (75.4)
No. of fresh cycles/woman 2.0 (1.0) 2.1 (0.9) 1.8 (0.9) 2.5 (1.1) 2.0 (0.9) 2.0 (0.9) 2.3 (1.1)
No. of FET cycles/woman 0.6 (1.1) 0.3 (0.7) 0.7 (1.2) 0.6 (0.9) 1.0 (1.3) 0.5 (1.0) 0.3 (0.7)
First cycle cancellation 93 (16.9) 16 (42) 0 19 (46) 0 15 (23) 43 (34.1)
FSH dose increased between
cycle 1 and 2
194/351 (55.3) 24/27 (89) 21/94 (22.3) 31/34 (91) 13/63 (20.6) 32/42 (76) 73/91 (80.2)
Amount of increase (IU/L) 56 (25) 61 (29) 51 (11) 57 (46) 57 (13) 54 (11) 57 (19)
Data are presented as mean (SD) or number (%) unless otherwise speciﬁed. AFC, antral follicle count (2–10 mm); AMH, anti-Müllerian hormone (ng/ml); IQR, interquartile range;
FET, frozen-thawed embryo transfer.
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a)
b)
Figure 2 Cumulative live birth curves for low-prognosis women over 18 months of IVF/ICSI treatment.Women were stratiﬁed
according to the POSEIDON criteria (Poseidon group et al., 2016), and the curves were calculated by using (a) the life table analysis (optimistic
approach) and (b) the competing risk method (conservative approach).
D
ow
nloaded from
 https://academ
ic.oup.com
/hum
rep/article-abstract/34/6/1030/5497452 by Erasm
us U
niversiteit R
otterdam
 user on 04 July 2019
POSEIDON criteria and cumulative live birth rates 1037
Table IV Pairwise log-rank comparisons of the ‘optimistic’ and ‘conservative’ cumulative incidence curves.
Adjusted P-values (Hommel, 1988)
Young
unexpected
poor
responder (1a)
Young
unexpected
suboptimal
responder (1b)
Older
unexpected
poor
responder (2a)
Older
unexpected
suboptimal
responder (2b)
Young
expected poor
responder (3)
.....................................................................................................................................................................................
Optimistic
Younger unexpected
suboptimal responder (1b)
0.824 - - - -
Older unexpected poor
responder (2a)
0.504 0.041∗ - - -
Older unexpected suboptimal
responder (2b)
0.988 0.051 0.860 - -
Younger expected poor
responder (3)
0.988 0.670 0.504 0.985 -
Older expected poor
responder (4)
0.160 <0.001∗ 0.988 0.448 0.075
Conservative
Younger unexpected
suboptimal responder (1b)
0.810
Older unexpected poor
responder (2a)
0.551 0.048∗
Older unexpected suboptimal
responder (2b)
0.810 0.034∗ 0.810
Younger expected poor
responder (3)
0.979 0.720 0.551 0.800
Older expected poor
responder (4)
0.053 <0.001∗ 0.979 0.285 0.022∗
∗A p-value of < 0.05 is considered to indicate a statistically signiﬁcant difference in CLBR over 18 months of IVF/ICSI treatment
reveals that ∼56% has a live birth after 18 months of IVF/ICSI
treatment. A considerable variation is seen between the POSEIDON
groups, which is primarily attributable to a woman’s age. Younger
women had the highest CLBR, without a large impact of the ﬁrst
cycle ovarian response on the prognosis over 18 months. The CLBRs
of older women were lower, especially for those with an impaired
ovarian reserve, but still exceeded ∼39%.
Explanation of ﬁndings
These ﬁndings are in line with several studies that demonstrated female
age to be the main predictor of pregnancy in IVF/ICSI treatment
(van Loendersloot et al., 2010; Broer et al., 2013; McLernon et al.,
2016). The distinct role of a woman’s age on the reproductive
capacity is explained by the age-related decline in oocyte quality, which
coincides with a progressive decrease in the primordial follicle number
(Broekmans et al., 2009; Cimadomo et al., 2018). As a consequence,
the number of euploid embryos in IVF/ICSI treatment rapidly
decreases after the age of 35 (Franasiak et al., 2014; Demko et al.,
2016), which most likely explains the substantially lower CLBR in the
older subgroups.
The variation in CLBR between the POSEIDON subgroups was
secondarily attributable to the quantitative parameters. This is in line
with studies that show that, within speciﬁc age categories, lower AMH
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levels and a reduced ovarian response are associated with a decreased
probability of a live birth (Sunkara et al., 2011; Hamdine et al., 2015;
Polyzos et al., 2018). Yet, female age had a much more signiﬁcant
impact on the CLBR than the quantitative parameters, which is
probably explained by the higher importance of the quality of the
oocyte, as opposed to their number, in order to obtain a good
quality embryo with a high implantation capacity (Baart et al., 2007;
Arce et al., 2014).
Not all low-prognosis women had substantially reduced pregnancy
prospects. The 18-month CLBR of the younger unexpected poor
and suboptimal responders approached those of normal responders,
who are generally considered to have optimal prospects in IVF/ICSI
treatment. These ﬁndings are comparable to previous studies that
evaluated CLBR of unexpected poor responders over multiple cycles
(Klinkert et al., 2004; Hendriks et al., 2008; Oudendijk et al., 2012;
Moolenaar et al., 2013). Although the pathophysiologic mechanism
of the hypo-responsiveness is not fully understood in these younger
women (Alviggi et al., 2018), it is unlikely to be related to a reduced
oocyte quality (Morin et al., 2018), which probably explains the rela-
tively high CLBR over multiple IVF/ICSI cycles.
As the CLBR is calculated over 18 months of treatment, the
success rates over consecutive cycles determine the prognosis of each
of the subgroups. Variation exists in the success rates of subsequent
treatment cycles between the subgroups, which may be partly related
D
ow
nloaded from
 https://academ
ic.oup.com
/hum
rep/article-abstract/34/6/1030/5497452 by Erasm
us U
niversiteit R
otterdam
 user on 04 July 2019
1038 Leijdekkers et al.
to differences in the effect of therapeutic adjustments between
cycles. Still, the differences in baseline characteristics, including female
age and ovarian reserve status, will mainly determine the LBR in
the subsequent treatment cycles, as is illustrated by the persisting
low LBR in subsequent cycles in older women with an impaired
ovarian reserve.
Strengths
This study initiates the essential validation of the POSEIDON criteria
and provides valuable information on long-term pregnancy prospects
of the proposed groups. In recent years, embryo cryopreser-
vation has become an integral part of IVF/ICSI treatment, and many
couples have more than one fresh treatment cycle (Wong et al., 2014;
McLernon et al., 2016). Therefore, evaluating CLBR over multiple
complete cycles, instead of studying single fresh cycle results, provides
a more comprehensive overview of the chance of success over an
entire treatment period.
CLBRs are often overestimated due to the use of optimistic analytic
approaches (Stolwijk et al., 1996). In this study, both an optimistic
and a conservative approach were applied. This assured the robust-
ness of the ﬁndings and carefully addressed the issue of treatment
discontinuation, which is of particular importance in low-prognosis
women.
The prospective design of the OPTIMIST study ensured reliable
data collection with relatively low rates of missing values. Multiple
imputation was applied to handle missing data, which is considered
to be the preferred strategy for ‘missings (completely) at random’ to
prevent biased estimates, to increase precision, and to avoid the waste
of resources (Sterne et al., 2009; Janssen et al., 2010).
Limitations
The primary limitation of this study was the relatively small num-
bers in some of the subgroups, limiting the power to detect sta-
tistically signiﬁcant differences and decreasing the precision of the
estimates. Although this hindered the drawing of ﬁrm conclusions,
our ﬁndings still provide the ﬁrst meaningful indication of the pro-
portion, characteristics, and prognosis of women in the POSEIDON
groups.
Second, the majority of blood samples were obtained during
downregulation with a GnRH agonist, which may have slightly affected
serum AMH levels (Wang et al., 2007; Jayaprakasan et al., 2008;
Su et al., 2013). However, as such a change most likely reﬂects a
change in the follicle number and follicle size distribution, the accuracy
to predict the ovarian response is unlikely to be compromised, as was
conﬁrmed by a previous study (Wang et al., 2007; Cai et al., 2018). In
the POSEIDON classiﬁcation, AMH is used as an ovarian response
predictor to categorize women into expected and unexpected
poor responders. As AMH maintains its predictive accuracy when
measured during downregulation, the AMH values in the current study
allowed for a valid and accurate classiﬁcation of the low-prognosis
women, and no large impact on the CLBR of the POSEIDON groups
is expected.
Furthermore, all women started with a ﬁxed FSH dose of 150 IU/-
day, which may be considered as a low dose for women with an
expected poor response. However, as previous studies revealed no
beneﬁcial impact of increased FSH doses on CLBR, it is unlikely that a
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higher starting dose would have altered our ﬁndings (van Tilborg et al.,
2017b; Lensen et al., 2018). Also, small dose adjustments between
cycles were permitted, which could have induced therapeutic differ-
ences between the subpopulations. Yet, as such dose adjustments
closely reﬂect current practice, this allows for a greater generalizability
of our ﬁndings.
Finally, the inclusion of multiple centers in the OPTIMIST study
resulted in some between-center variation in treatment protocols
among the included women, which may have inﬂuenced the success
rates of treatment. Yet, as such variation mirrors the actual differences
between infertility clinics, this also increases the representability of the
results.
Implications
The recently introduced POSEIDON criteria identify low-prognosis
women in IVF/ICSI treatment and combine quantitative and qualitative
parameters to provide a more detailed stratiﬁcation into homogenous
groups (Poseidon group et al., 2016). This validation study shows the
variation in CLBR between the proposed groups and reveals a primary
role of female age, reﬂecting the importance of oocyte quality in the
probability of a live birth.
For younger low-prognosis women, who generally have high-quality
oocytes, the ﬁndings suggest that the quantitative parameters are
of limited importance for their pregnancy prospects over multiple
treatment cycles. Therefore, the question rises whether these women
should be considered to have a low prognosis in clinical practice,
especially as the present results suggest that current clinical manage-
ment achieves relatively high CLBR over 18 months of treatment.
For older low-prognosis women, a higher oocyte yield may be
needed to compensate for the decreased oocyte quality. However, the
age-related decline is generally accompanied by a decreased size of the
primordial follicle pool, which hinders the retrieval of a high number
of oocytes (Broekmans et al., 2007). Therapeutic interventions that
aim to improve the ovarian response, such as the use of increased
doses of gonadotropins or co-treatment with growth hormone,
dehydroepiandrosterone, or testosterone, have all failed to improve
clinical outcomes in these women (Pandian et al., 2010; Nagels et al.,
2015; Lensen et al., 2018). Also, no treatment options are available
that target oocyte quality.
Therefore, the medical management of the older low-prognosis
women remains particularly difficult and forms a challenge in IVF/ICSI
treatment. Until new therapeutic interventions become available for
this group, increasing awareness about the age-related decline in repro-
ductive chances is needed to manage expectations and to inform
younger women about fertility preservation options such as oocyte
cryopreservation.
Conclusion
In conclusion, the CLBR of low-prognosis women is on average
∼56% over 18 months of IVF/ICSI treatment, and varies considerably
between the POSEIDON groups. The variation is primarily determined
by female age, which reﬂects the importance of oocyte quality.
In the younger groups, relatively high CLBRs are reached over
18 months of treatment, despite reduced quantitative parameters.
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In the older groups, the CLBRs are substantially lower, and as no
effective interventions exist to counteract the reduced oocyte quality,
expectations should be managed before initiating treatment.
Supplementary data
Supplementary data are available at Human Reproduction online.
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